Market Overview

Celgene Says ABRAXANE Demonstrates Statistically Significant Improvement

Share:
Related CELG
Stocks That Battle Cancer Were The Best-Performing Biotechs In January
Celgene's EPS Contain 'Few Surprises,' Baird Says
2 Biotech Juggernauts That Belong In Every Growth Portfolio (Seeking Alpha)

Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that its phase III study of ABRAXANE^® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival. In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone.

Posted-In: News FDA

 

Related Articles (CELG)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional